Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The objective of this study was to find out whether the bioavailability of PT Dexa Medica's formulation of 4 mg perindopril tert-butylamine tablets was equivalent to that of the innovator's product (Prexum® 4 mg, Servier).

Condition or disease	Intervention/treatment	Phase
Healthy	Drug: Perindopril 4 mg tablets of PT Dexa Medica; Drug: Perindopril 4 mg tablets of Servier	Not Applicable

Detailed Description:

The participating subjects were required to have an overnight fast and in the next morning were given orally one tablet of the test drug (Perindopril 4 mg tablets of PT Dexa Medica) or one tablet of the reference drug (Prexum® 4 mg, Servier).

Blood samples were drawn immediately before taking the drug (control), and at 20, 40 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 192 hours after drug administration.

Three weeks after the first drug administration (washout period), the procedure was repeated using the alternate drug.

The pharmacokinetic parameters, including AUCt, AUCinf, Cmax, t max, and t1/2, were determined based on the concentrations of the perindopril parent compound and the metabolite perindoprilat, using high-performance liquid chromatography method with tandem mass spectrometry detector (LC-MS/MS).

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	18 participants
Allocation:	Randomized
Intervention Model:	Crossover Assignment
Masking:	Single (Investigator)
Primary Purpose:	Treatment
Official Title:	Bioequivalence Study of 4 mg Perindopril Tablets Produced by PT Dexa Medica in Comparison With the Reference Tablets (Prexum® 4 mg, Servier)Under Fasting Condition
Study Start Date :	September 2008
Actual Primary Completion Date :	November 2008
Actual Study Completion Date :	December 2008

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Perindopril 4 mg tablets of PT Dexa Medica; Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg. A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects.	Drug: Perindopril 4 mg tablets of PT Dexa Medica; Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.; Other Names: Test Product: Perindopril 4 mg tablets of PT Dexa Medica.; Each tablet contains perindopril tert-butylamine salt 4 mg
Active Comparator: Perindopril 4 mg tablets of Servier; Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg. A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects.	Drug: Perindopril 4 mg tablets of Servier; Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.; Other Names: Reference product: Prexum® 4 mg, produced by Servier.; Each tablet contains Perindopril tert-butylamine salt 4 mg.

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Area under concentration-time curve (AUC)of perindopril parent compound [ Time Frame: 192 hours ]
   Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of perindopril parent compound.
2. Area under concentration-time curve (AUC)of perindoprilat [ Time Frame: 192 hours ]
   Relative bioavailability (primarily measured by AUCt and AUCinf) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The AUC was measured based on the plasma concentration of the active metabolite, perindoprilat.

Secondary Outcome Measures :

1. Peak plasma concentration (Cmax)of perindopril parent compound [ Time Frame: 192 hours ]
   Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of perindopril parent compound.
2. Peak plasma concentration (Cmax)of perindoprilat [ Time Frame: 192 hours ]
   Relative bioavailability (secondarily measured by Cmax) between two perindopril 4 mg tablet formulations (test and reference formulations) under fasting condition. The Cmax was measured based on the plasma concentration of the active metabolite, perindoprilat.
3. Time to achieve the peak plasma concentration (tmax)of perindopril parent compound [ Time Frame: 192 hours ]
4. Time to achieve the peak plasma concentration (tmax)of perindoprilat [ Time Frame: 192 hours ]
5. Elimination half-life (t1/2)of perindopril parent compound [ Time Frame: 192 hours ]
6. Elimination half-life (t1/2)of perindoprilat [ Time Frame: 192 hours ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 55 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

• Healthy male and female subjects
• Aged 18-55 years inclusive
• A body mass index in the range of 18-25 kg/m2
• Able to participate, communicate well with the investigators and willing to give informed consent
• Non-smokers

• Vital signs (after 10 minutes resting) are within the following ranges:

  • systolic blood pressure 100-125 mmHg
  • diastolic blood pressure 60-80 mmHg
  • pulse rate 60-90 bpm

Exclusion Criteria:

• Pregnant or lactating women
• Known hypersensitivity or contraindication to perindopril
• Intake of any prescription drug within 14 days of this study's first dosing day
• Intake of any non-prescription drug, food supplement, or herbal medicine within 7 days of this study's first dosing day
• History or presence of any liver dysfunction (ALT, alkaline phosphatase, total bilirubin ≥ 1.5 ULN)
• History of any bleeding or coagulation disorders
• Clinically significant ECG abnormalities
• Clinically significant haematology abnormalities
• Renal insufficiency (plasma creatinine concentration ≥ 1.4 mg/dL)
• Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug
• A donation or loss of 500 mL (or more) of blood within 3 months before this study's first dosing day
• A positive hepatitis B surface antigen (HBsAg), anti-HCV, and anti-HIV
• History of drug or alcohol abuse within 12 months prior to screening of this study
• Participation in a previous study within 3 months of this study's first dosing day

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

Indonesia
PT Equilab International
Jakarta, Indonesia, 12430

Sponsors and Collaborators

Dexa Medica Group

Investigators

Principal Investigator:	Danang A Yunaidi, MD	PT. Equilab International

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications:

Bellissant E, Giudicelli JF. Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients. Br J Clin Pharmacol. 2001 Jul;52(1):25-33.

Louis WJ, Workman BS, Conway EL, Worland P, Rowley K, Drummer O, McNeil JJ, Harris G, Jarrott B. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol. 1992 Sep;20(3):505-11.

Sennesael J, Ali A, Sweny P, Vandenburg M, Slovic D, Dratwa M, Resplandy G, Genissel P, Desche P. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. Br J Clin Pharmacol. 1992 Jan;33(1):93-9.

Responsible Party:	Dexa Medica Group
ClinicalTrials.gov Identifier:	NCT01682577 History of Changes
Other Study ID Numbers:	PR.122/EQL/2008
First Posted:	September 11, 2012
Last Update Posted:	September 11, 2012
Last Verified:	September 2012

Keywords provided by Dexa Medica Group:

Perindopril; Perindoprilat; Bioequivalence; Pharmacokinetic; Angiotensin-converting enzyme inhibitor

Additional relevant MeSH terms:

Angiotensin-Converting Enzyme Inhibitors; Perindopril; Protease Inhibitors	Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents